Tirzepatide stories

Sep 30, 2026

Eli Lilly's amylin-Zepbound combination shows record 23% weight loss in diabetes trial

Eli Lilly reported that its experimental combination of amylin drug eloraTZP with Zepbound (tirzepatide) achieved up to 23% weight loss in patients with type 2 diabetes and obesity, outperforming Zepbound alone and representing the highest weight loss seen in similar studies to date.

Sep 30, 20266 sources

May 1, 2026

FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

FDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

May 1, 20261 source

Apr 18, 2026

Weight Loss Medications Lead to Notable Muscle Loss Alongside Fat Loss

UNC School of Medicine study finds incretin-based medications including semaglutide and tirzepatide cause significant muscle loss in addition to fat reduction, raising concerns about long-term metabolic effects.

Apr 18, 20261 source

Apr 10, 2026

AI Analysis of 400,000 Reddit Posts Identifies Overlooked GLP-1 Drug Side Effects

University of Pennsylvania researchers used AI to analyze over 400,000 Reddit posts to identify patient-reported symptoms associated with semaglutide and tirzepatide that may not be captured in clinical trials.

Apr 10, 20261 source

Top claims

▪Eli Lilly's EloraTZP combination approach targets three nutrient-stimulated hormone pathways—GLP-1, GIP, and amylin—to lightly engage multiple natural satiety systems rather than heavily targeting a single hormone system
▪EloraTZP combines eloralintide, an experimental selective amylin receptor agonist mimicking the pancreatic hormone amylin that signals fullness, with tirzepatide, the active ingredient in Eli Lilly's Zepbound and Mounjaro that targets GLP-1 and GIP gut hormones
▪Eli Lilly plans to initiate Phase 3 clinical trials for the EloraTZP combination treatment by the end of 2026, which will include adjusted dosing schedules to improve tolerability

Topics

Zepbound Eli Lilly Weight management Clinical trials Drug development Metabolic health Drug Approval and Clinical Trials Novo Nordisk Lifestyle, Wellness and Nutrition GLP-1 medications Healthcare Policy Environmental and Occupational Health Nutrition & diet hacking AI data analysis AI safety & social impact AI privacy & surveillance AI research & benchmarks Health AI

Related entities

Liraglutide Semaglutide